Intranasal DHE: Promising Relief for Acute Migraine Attacks
- MigraineMind
- Dec 5, 2025
- 1 min read
Research Summary
A recent study published in the Annals of Pharmacotherapy explores a new intranasal powder formulation of dihydroergotamine (DHE) for acute migraine treatment. Researchers analyzed four studies on this formulation, highlighting its rapid absorption with a maximum concentration reached in about 0.5 hours and a half-life of 12 hours. A 12-month safety study noted mostly mild to moderate side effects. In terms of pain relief, 13% of participants experienced pain freedom at 1 hour, increasing to 37% at 2 hours and 67% at 4 hours post-dose. Despite promising pharmacokinetic properties, it is not yet recommended as a first-line migraine treatment.
Study Details
👥 Research Team: Terpening CM, Wietholter JP
📚 Published In: Ann Pharmacother
📅 Publication Date: 2025 Dec 4
⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.